Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
| (1) | Registration Statement (Form S-8 No. 333-289494) pertaining to the 2024 Equity Incentive Plan, as amended of Protara Therapeutics, Inc., |
| (2) | Registration Statement (Form S-8 No. 333-281286) pertaining to the 2024 Equity Incentive Plan and the 2024 Employee Stock Purchase Plan of Protara Therapeutics, Inc., |
| (3) | Registration Statement (Forms S-8 Nos. 333-277931, 333-270354, 333-263392, and 333-254124) pertaining to the Amended and Restated 2014 Equity Incentive Plan, as amended and the 2014 Employee Stock Purchase Plan of Protara Therapeutics, Inc., |
| (4) | Registration Statement (Form S-8 Nos. 333-237497 and 333-285568) pertaining to the ArTara Therapeutics, Inc. Inducement Plan of Protara Therapeutics, Inc., |
| (5) | Registration Statement (Form S-8 No. 333-235918) pertaining to the Proteon Therapeutics, Inc. Amended and Restated 2014 Equity Incentive Plan, as amended and ArTara Subsidiary, Inc. 2017 Equity Incentive Plan of Protara Therapeutics, Inc., and |
| (6) | Registration Statement (Form S-3 Nos. 333-275290 and 333-279067) of Protara Therapeutics, Inc. |
of our report dated March 10, 2026, with respect to the consolidated financial statements of Protara Therapeutics, Inc. included in this Annual Report (Form 10-K) of Protara Therapeutics, Inc. for the year ended December 31, 2025.
| /s/ Ernst & Young LLP | |
| New York, New York | |
| March 10, 2026 |